Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression is a research paper published in Cancers (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: R21CA273739
NIH
Grant: UM1AI120176
NIH
Grant: R33AI149665
NIH
Grant: U01AI148055
NIH
Grant: GM007750
National Institutes of Health
Grant: 5T32GM007750-19
DRUG ACTION, METABOLISM AND KINETICS
National Institutes of Health
Grant: 1U01AI148055-01
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"
National Institutes of Health
Grant: 5R21CA273739-02
Drug combination nanoparticles for advanced treatment of metastatic TNBC
European Commission
Grant: 273739
Context-Aware Recommender Systems (CARS)
National Institutes of Health
Grant: 5R33AI149665-04
NextGen Long-acting and targeted combination ART for Children with HIV
National Institutes of Health
Grant: 1UM1AI120176-01
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)
FWCI
0.12
Citation Percentile
0.4%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals